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Abstract The Rho subgroup of the Rho GTPases consisting
of RhoA, RhoB and RhoC induces a specific type of actin
cytoskeleton and carry out a variety of functions in the cell.
mDia and ROCK are downstream effectors of Rho mediating
Rho action on the actin cytoskeleton; mDia produces actin
filaments by nucleation and polymerization and ROCK
activate myosin to cross-link them for induction of actomy-
osin bundles and contractility. mDia is potentially linked to
Rac activation and membrane ruffle formation through c-Src-
induced phosphorylation of focal adhesion proteins, and
ROCK antagonizes this mDia action. Thus, cell morphogen-
esis, adhesion, and motility can be determined by the balance
between mDia and ROCK activities. Though they are not
oncogenes by themselves, overexpression of RhoA and RhoC
are often found in clinical cancers, and RhoC has been
repeatedly identified as a gene associated with metastasis. The
Rho-ROCK pathway is implicated in Ras-mediated transfor-
mation, the amoeboid movement of tumor cells in the three-
dimensional matrix, and transmigration of tumor cells through
the mesothelial monolayer. On the other hand, the Rho-mDia1
pathway is implicated in Src-mediated remodeling of focal
adhesions and migration of tumor cells. There is also an
indication that the Rho pathway other than ROCK is involved
in Src-mediated induction of podosome and regulation of
matrix metalloproteases. Thus, Rho mediates various pheno-
types of malignant transformation by Ras and Src through its
effectors, ROCK and mDia.
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1 Rho signaling; ROCK and mDia1
The Rho family of GTPases has now expanded, consisting
of more than 20 members [1, 2]. By Rho we refer here to
prototypical members of Rho in a narrower sense, namely,
RhoA, RhoB and RhoC, and review implication of their
signaling in cancer, because these three Rho GTPases share
the same group of effectors and are supposed to have
similar mode of actions. Rho in this definition functions as
a molecular switch in cellular processes such as cell
morphogenesis, adhesion, migration and cell cycle progres-
sion including cytokinesis [1, 2]. Their conversion from the
GDP-bound inactive form to the GTP-bound active form is
catalyzed by the Dbl family of Rho GTPase-specific
guanine nucleotide exchange factors (Rho GEFs) [3] and
conversion from the GTP-bound form to the GDP-bound
form is carried out by intrinsic GTPase activity stimulated
by Rho-specific GTPase activating proteins (Rho GAPs)
[4]. The primary action of Rho is to induce a specific type
of actin cytoskeleton in the cell. Rho also modulates local
dynamics of microtubules (MTs) in a stimulus-dependent
manner, stabilizing a subset of microtubules. Typical actin
cytoskeletons induced by Rho are stress fibers running in
an interphase cell, and the contractile ring formed in a
mitotic cell (Fig. 1a). Both stress fibers and the contractile
ring are actomyosin bundles composed of anti-parallel actin
filaments cross-liked by myosin. It is therefore reasoned
that Rho induces production of actin filaments and
activation of myosin, and locates thereby formed actomy-
osin bundles at different sites of a cell dependent on a phase
of cell cycle (Fig. 1b). These actions of Rho are elicited by
effectors that are activated downstream of Rho (Fig. 2a).
There are two major effectors for Rho; one is ROCK (Rho-
associated coiled-coil forming kinase) (Rho kinase/ROK)
[5–7] and the other is mDia (mammalian homolog of
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Drosophila diaphanous) [8]. mDia is a formin molecule that
catalyzes actin nucleation and polymerization and produces
long, straight actin filaments [9], whereas ROCK is a
serine/threonine kinase that can phosphorylate a variety of
substrates [10]. One major substrate for ROCK is the
myosin-binding subunit of myosin phosphatase, and ROCK
inactivates it by phosphorylation [11, 12]. ROCK can also
directly phosphorylate myosin light chain [13]. These two
actions of ROCK, as a consequence, increase the myosin
light chain phosphorylation, stimulate cross-linking of actin
by myosin and enhance actomyosin contractility. ROCK
also phosphorylates and activates LIM-kinase, which in
turn phosphorylates and inactivates actin-depolymerizing
and severing factor, cofilin [14]. This latter action of ROCK
results in stabilization of existing actin filaments and
increase in their content. It is presumed that these actions
of ROCK and mDia on actin and myosin are combined
downstream of Rho to induce actomyosin bundles in the
cell (Fig. 2b). Indeed, expression of an active form of mDia
induces stress fibers in cultured cells, and treatment of these
cells with a specific ROCK inhibitor, Y-27632 [15], causes
dissolution of the bundles, leaving the cells with diffusely
distributed actin filaments [16]. Requirement of ROCK and
mDia in the contractile ring formation and function was
also reported [17, 18].
Thus, cooperation of mDia and ROCK is required for
assembly of actomyosin bundles such as stress fibers and
the contractile ring. However, expression of constitutive
active forms of ROCK alone results in disorganized
actomyosin bundles by random bundling of actin filaments
and cell contraction [19]. Co-expression of active mDia1
can correct this aberrant contraction by active ROCK and
aligns actomyosin bundles as seen in stress fibers [16].
These results indicate that mDia may transmit a signal to
modulate the ROCK action. Tsuji et al. [20] examined this
issue by treating serum-starved Swiss3T3 cells either with
botulinum C3 exoenzyme that blocks total Rho signaling
[21] or with Y-27632 that inhibits the ROCK branch of Rho
signaling and leaves the mDia branch intact. They
compared the lysophosphatidic acid (LPA) -induced mor-
phology of these cells, and found that treatment with
Y-27632 results in formation of membrane ruffles. Analyz-
ing the signaling mechanism therein, they found that the
Rho-mDia1 signaling leads to activation of Rac through Src
activation and the phosphorylation-dependent formation of
Cas/Crk/DOCK180 complex, and that this pathway is
suppressed by the ROCK activity. Thus, ROCK and mDia
antagonize in Rho-dependent Rac activation, and the
balance between the two pathways appears to determine
the cell shape and pattern of stress fibers (Fig. 3). This
mechanism appears to operate not only in fibroblasts but
also in other types of cells. Opposing actions of mDia and
ROCK were also reported in epithelial cells, though
signaling pathways therein were not defined. There, mDia1
facilitates and ROCK disrupts cell-cell adhesion [22]. More
consistent with the Tsuji’s finding, Arakawa et al. [23] used
cultured cerebellar granule neurons, and examined involve-
ment of mDia in SDF1α-induced neurite extension. They
found that mDia1 can potentially activates Rac and
facilitates axonal elongation but this action is tonically
suppressed by the action of ROCK. Titration of intact Rho
molecules with varying doses of C3 exoenzyme exhibited
the biphasic response, that is, elongation at lower concen-
trations and suppression at higher concentrations. Given
that activation of ROCK causes neurite retraction, these
results indicates that a high level of active Rho activates
both ROCK and mDia1 to induce retraction, whereas a
lower level of Rho preferentially activates mDia1 to induce
neurite elongation (Fig. 4). This view is consistent with the
reported Kd values of the Rho-binding domains of ROCK
Fig. 1 (a) Stress fibers and the contractile ring, two typical actin
cytoskeletons induced by Rho. Both structures are composed of anti-
parallel actin filaments cross-linked by myosin II. (b) Presumed Rho-
regulated steps in assembly of actomyosin bundles. Rho is supposed
to catalyze actin nucleation and polymerization to form actin filaments
and activate myosin to cross-link them
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and mDia for the GTP-bound form of Rho, 130 and 6 nM,
respectively [24, 25], and can be useful in interpreting Rho
actions in various settings and those exerted spatiotempo-
rally at different locations in a single cell (see below).
2 ROCK and mDia in cell migration
Earlier studies examining the role of Rho GTPases in cell
migration used migration in two-dimensional culture for
analysis such as the in vitro wound-healing assay or the
assay using the Dunn chemotactic chamber [26, 27]. In
these assays, cells migrate to the wound or to the
chemotactic stimuli by polarizing to the direction of
migration with extending protrusions at the front and the
retracting tail at the rear [28] (Fig. 5a). Migrating cells then
make adhesions to extracellular matrix (ECM) to stabilize
the forward protrusion. Adhesions to ECM are used as sites
to pull the cell body forward and are subsequently
disassembled as the cell moves over them. This cycle of
events enables cells to migrate to their destination. The
actin cytoskeleton and microtubules (MTs) work critically
in these events. Actin polymerization at the leading edge
drives membrane protrusion, the association of the actin
cytoskeleton with integrins regulate their binding to ECM,
and the actin bundles within the body generate tension to
pull the cell body forward and retract the tail. MTs are also
polarized in migrating cells and are essential for the
directed migration of many cell types, possibly by delivery
of signaling molecules and membrane components [28].
Previous studies analyzing the effects of dominant active
and negative mutants of Rho GTPases on this type of
migration demonstrated that Cdc42 regulates cell polarity
and Rac functions for membrane protrusion [26, 27]. One
well-characterized action of Cdc42 in cell polarity is to
orient the MT organizing center (MTOC) as well as the
Fig. 2 (a) Rho effectors. Ef-
fector molecules for Rho are
categorized by similarity of their
domain structure. RBD, Rho-
binding domain; PH, pleckstrin
homology domain; FH, formin
homology domain. ROCK has
two isoforms, ROCK-I and
ROCK—II, and mDia has three
isoforms, mDia1, mDia2 and
mDia3. PKN, Rhophilin and
Rhotekin contain the homolo-
gous Rho-binding domain of
about 90 amino acid stretch. (b)
Site and mechanism of actions
of mDia1 and ROCK in Rho-
induced assembly of actomyosin
bundles. mDia1 catalyzes actin
nucleation and polymerization
to form actin filaments. ROCK
activates myosin to cross-link
them. ROCK also inactivates
cofilin through LIM-kinase and
inhibits actin severing and de-
polymerization
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Golgi apparatus in front of the nucleus toward the leading
edge [26], Subsequent studies showed that Cdc42 is indeed
active at the cell front [29], and that Cdc42 activates the
Par6-atypical protein kinase C (aPKC) complex there,
which leads to MTOC orientation through local inhibition
of GSK3β and accumulation of adenomatous polyposis coli
protein (Apc) at the ends of microtubules in the leading
edge [30, 31]. More recently Gomes et al. [32] suggest that
the Cdc42/Par6/aPKC pathway described above maintains
MTOC and Golgi at cell centroid through the microtubule-
dynein interaction, while Cdc42 also induces actomyosin-
dependent rearward pulling of the nuclei, and that the net
action of the two forces results in MTOC orientation. As for
membrane protrusion, Rac is shown to be active in the front
of migrating cells [29, 33] and is thought to induce
membrane protrusion by stimulating actin polymerization
through activation of the WAVE-Arp2/3 complex pathway
(see for review, [34]). Comparing with these Cdc42 and
Rac actions, little is known concerning the role of Rho in
cell migration [26, 28]. This is because inactivation of Rho
abolishes cell adhesion almost completely and makes
Fig. 5 (a) Cell migration in two-dimensional culture. Cells migrating
in two-dimensional culture polarize to the direction of migration with
membrane protrusions at the front and retraction at the tail. Micro-
tubules extending to the front are stabilized and the microtubule
organizing center (MTOC) is positioned in front of the nucleus. (b)
Impaired tail retraction by inhibition of the Rho-ROCK signaling.
Neutrophils treated with C3 exoenzyme or Y-27632 show marked
elongation of the cell body due to impaired tail retraction (Reprinted
with modification from Fig. 1 of reference 36 with permission from
Elsevier and courtesy of Naoko Yoshinaga-Ohara and Masataka
Sasada of Kyoto University)
Fig. 4 Diversion of Rho signaling is dependent on the local level of
Rho-GTP. Arakawa et al. (23) found in neuronal cells that the high
level of Rho-GTP induces ROCK activation and actomyosin contrac-
tility, whereas the low level of Rho-GTP preferentially activates
mDia1 and induces Rac activation, resulting in neurite retraction and
elongation, respectively. Similar mechanism appears to operate in
other types of cells and in different contexts (see text)
Fig. 3 Potential antagonism of the Rho-ROCK and the Rho-mDia1
pathways. mDia1 can potentially activate Rac through mobilization of
c-Src and the Cas-Crk-DOCK180 complex formation. ROCK inhibits
the mDia1-Rac pathway, whereas Rac can antagonize ROCK action.
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further analysis difficult [26]. Availability of selective
ROCK inhibitor such as Y-27632 [12, 15] or introduction
of RNAi in mammalian cells [23] has enabled us to
manipulate selectively each signaling downstream of Rho
and to define respective roles. One of the earliest studies
along this approach revealed that the Rho-ROCK signaling
is involved in tail retraction. Worthylake et al. [35] studied
requirement of Rho-ROCK signaling in transendothelial
migration of monocytes and found that this signaling is
dispensable for attachment, spreading and crawling of
monocytes on and through the endothelial layer but is
required for tail retraction for completion of diapedesis.
They reported that the ROCK signaling is necessary to
negatively regulate integrin adhesions in the tail. The action
of Rho signaling in tail retraction was also demonstrated in
a simpler system. Yoshinaga-Ohara et al. [36] loaded
neutrophils with C3 exoenzyme, and studied the chemo-
tactic behavior of C3-treated neutrophils to FMLP. They
found that Rho inhibition by C3 treatment did not interfere
with development of polarity and protrusion of pseudopo-
dia but impaired uropod detachment. Nonetheless, the
movement of the front and cell body continued, and, as a
result, C3-treated neutrophils exhibited abnormally elon-
gated cell bodies (Fig. 5b). Worthylake and Burridge [37]
further examined the mechanism of ROCK-mediated tail
retraction and found that tail detachment by ROCK is not
caused by myosin-based contractility, but due to attenuation
of integrin-mediated adhesion. Given the fact that ROCK
mediate clustering of integrin and induces large focal
adhesions in fibroblasts (see fro example, 19), the mecha-
nism suggested by their study appears paradoxical. They
suggested, however, that leukocytes does not possess
mature focal adhesions as seen in fibroblasts, but form
small focal complexes of tethering and signaling molecules
surrounding ligand-engaged integrins, and that ROCK is
required to suppress them. Their findings that inhibition of
ROCK in leukocytes increases the number of focal
complexes and at the same time induces extensive ruffles
around the perimeter of a cell may suggest that ROCK
suppresses Rac-induced focal complexes and ruffle forma-
tion spatiotemporally (see below).
Compared to ROCK, study on the role of mDia in cell
migration was slow due to the lack of appropriate experimen-
tal tool, but has recently been accelerated by introduction of
RNAi. Grosse and collaborators [38] analyzed migration of
mouse embryonic fibroblasts deficient in Gα12 and 13 in the
wound-healing assay. G α12 and 13 are known to couple to
Rho activation via a group of RGS-containing Rho GEFs
including p115Rho-GEF and LARG (see for review, [39]).
They found that MEF cells deficient in both G proteins
exhibited impaired Rho activation during migration, and that
the loss of Rho activation results in migration defects and
impaired stabilization of microtubules directed to the front.
They further observed that Rho co-localizes with mDia1 in
the front edge of migrating cells and that depletion of mDia1
by RNAi also interfered with cell migration and MT
stabilization. These results thus suggested requirement of
Rho for cell migration in addition to that of Rac and Cdc42
shown in previous studies. Yamana et al. [40] also used
RNAi for mDia1 in rat C6 glioma cells, and showed
requirement of the Rho-mDia1 pathway in cell migration
not only in the wound-healing assay but also in the Matrigel
transwell assay. Their analysis in the Dunn chamber further
showed that both directionality and locomotion were
impaired in mDia1-depleted cells. Consistently, they found
that mDia1 depletion interfered with not only MT stabiliza-
tion as Grosse and collaborators found, but also cell
polarization and focal adhesion turnover. By analyzing the
mechanism underlying the polarization defect, they found
that accumulation of Cdc42 and Apc at the front was
impaired, and, by analyzing the mechanism for the defect in
adhesion turnover, they found that c-Src accumulation and
subsequent protein tyrosine phosphorylation in focal adhe-
sions were impaired, in mDia1-depleted cells. c-Src was
previously shown to induce focal adhesion disassembly [41].
On the basis of these findings, they suggested that, in
migrating cells, the Rho-mDia1 pathway is activated in the
front and facilitates migration, on one hand, by MT-
dependent recruitment of Cdc42 and Apc in the front for
cell polarization, and, on the other hand, by actin-dependent
translocation of c-Src to focal adhesions to stimulate
adhesion turnover (Fig. 6).
The works by the Grosse’s group and Yamana et al. thus
clearly demonstrated the importance of Rho and its effector,
Fig. 6 Role of the Rho-mDia1 pathway in cell migration. Yamana et
al. (40) found that mDia1 localizes at the front of migrating cells, acts
on both actin and microtubules, and induces adhesion turnover and
cell polarization in rat C6 glioma cells
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mDia1, in cell migration, and suggested that this signaling
collaborates with Rac and Cdc42 in this process. However,
this view challenged the previous dogma that, among Rho
GTPases, only Rac and Cdc42 are important and Rho is
dispensable in cell migration. Furthermore, Arthur and
Burridge demonstrated that p190Rho-GAP is activated by
c-Src-dependent phosphorylation and the phosphorylated
form is abundant in migrating cells and functions to down-
regulate Rho [42, 43], further negating the role of Rho for
migration. However, the role of Rho for cell migration is
supported by a recent imaging study analyzing the
localization of active Rho in migrating fibroblasts. Hahn
and collaborators [44] developed a FRET biosensor for
active Rho by conjugating a YFP-RhoA and CFP-Rho
binding domain of Rhotekin, expressed in MEF cells, and
examined localization of active Rho in cells during
random migration or migration in the wound healing
assay. Consistent with the previous findings [43], the Rho
activity was minimal in the cell body. However, in
addition to the high Rho activity in the tail of robust
retraction, they found a sharp band of markedly higher
Rho activity immediately adjacent to the front edge of
cells with extending protrusion. This is consistent with the
role of mDia1 proposed by the studies of the Grosse’s
group and Yamana et al., and strengthens a significant role
Rho plays for cell migration.
3 Rho signaling in metastasis and invasion
Given the roles of Rho GTPases in cell adhesion and
migration, it is likely that they also play a role in tumor
metastasis and invasion. Survey of genes over-expressed in
clinical cancers and tumor cell lines showed frequent over-
expression of RhoA and RhoC (see for review, [45]). Of the
two, expression of RhoC was correlated with invasive
phenotype of clinical cancers. Earlier, Suwa et al. [46]
examined RhoA, RhoB and RhoC expression in 33 cases of
pancreatic ductal adenocarcinoma, and found that the
expression level of RhoC was higher in tumors than in
non-malignant tissues, higher in metastatic lesions than in
primary tumors, and correlated with perineural invasion and
lymph node metastasis and poorer prognosis, whereas
expression of either RhoA or RhoB did not show
correlation with these clinicopathological findings. The
RhoC gene was also identified experimentally as the gene
involved in metastasis by genomic analysis of highly
metastatic melanoma cells. Clark et al. [47] injected
A375P human melanoma cells or B16F0 mouse melanoma
cells intravenously into nude mice, dissected metastases
occurring in the lung, expanded cells of the metastatic
colonies in tissue culture and re-introduced into host mice.
Repeating this procedure three times, they isolated cell
populations with high metastatic potential from each cell
line. By comparing gene expression between these pop-
ulations and the parental populations with microarray
analysis, they detected three genes that were highly
expressed in all the metastatic tissues selected from both
cell lines; they were fibronectin, RhoC and thymosin β4.
The authors confirmed these genes derived from tumor
cells and not surrounding lung tissues, and verified
potential of RhoC as a metastasis gene by expressing
exogenous RhoC in melanoma cells and examining lung
metastasis. The selected metastatic cell population and the
cells over-expressing exogenous RhoC did not show
enhanced proliferation, but were more migratory and more
invasive and exhibited elongated morphology, the proper-
ties suppressed by expressing dominant negative Rho
mutant. This work thus confirmed experimentally the
importance of RhoC in metastasis. More recently, analysis
of microRNAs (miRNAs) expressed in breast cancer also
identified RhoC as a metastasis-associated gene. Ma et al.
[48] first detected 29 miRNAs that are differentially
expressed between primary breast carcinomas and normal
mammary tissues, then examined their expression in breast
cancer cell lines with metastatic potential, and identified
miR-10b as a candidate miRNA associated with metastasis.
They then analyzed functions of this miRNA, and found
that miR-10b regulates cell migration and invasion in vitro,
and initiates tumor invasion and distant metastasis in vivo.
Analyzing the mechanism by which miR-10b induces
tumor invasion, the authors found that miR-10b directly
inhibits translation of HOXD10, which results in release of
HOXD10-mediated inhibition of expression of genes
involved in cell migration including RhoC.
Thus, there is substantial amount of evidence for
involvement of RhoC in tumor metastasis. However, little
information is available how RhoC mediates such an
action. It remains unclear whether the metastatic potential
of RhoC is due to specific localization or specific upstream
or downstream signaling. Among RhoA, B and C, RhoB is
known to localize to endosomes, while no distinct
localization has been reported for RhoA and C [49]. It
was reported that RhoC expression leads to induction of
angiogenic factors in breast epithelial cells [50]. It was also
reported that RhoC interacts with ROCK more effectively
than RhoA and facilitates disruption of adherens junctions
of epithelial cells [20]. These mechanisms, particularly
preferential binding to ROCK, may partly explain the
mechanism of RhoC-mediated tumor invasion in vivo,
given ROCK-mediated disruption of cell-cell junction as
described above and ROCK-dependent transmigration and
amoeboid movement of tumor cells as described below,
though the morphology of RhoC-overexpressing cells is not
consistent with the rounded morphology of ROCK-activated
cells,
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The earliest indication for involvement of ROCK in
tumor invasion was obtained by transmigration experiment
of tumor cells. In order for tumor cells to establish
metastasis at sites distant from its origin and invade into
tissues, they have to transmigrate through host cell layers
such as the endothelial cell layer covering the blood vessels
and the mesothelial cell layer covering the peritoneum.
Starting with the finding that cultured rat MM1 hepatoma
cells required serum stimulation and intact Rho activity to
migrate through the mesothelial layer and establish tumor
foci beneath the monolayer in vitro [51], Itoh et al. [52]
examined involvement of ROCK in this process. They
found that transfection of dominant active mutants of
ROCK conferred MM1 cells the invasive activity indepen-
dent of Rho and serum, whereas expression of a dominant
negative ROCK mutant or treatment with a ROCK
inhibitor, Y-27632, substantially attenuated invasiveness
in vitro. Furthermore, continuous local infusion in vivo of
Y-27632 markedly reduced dissemination and tumor nodule
formation of MM1 cells injected into the peritoneal cavity
of syngeneic rats. Thus, the work by Itoh et al. demon-
strates that ROCK action is required not only for in vitro
models of tumor invasion but also for tumor invasion in
vivo. Given the work by Worthylake et al. on the role of
ROCK in tail retraction discussed above, one obvious
candidate of ROCK actions in this process is to retract tail
while the cell body creeps beneath the monolayer, although
there may be other ROCK actions that facilitate tumor
invasion in vivo, one being ROCK-mediated tumor cell
migration in the matrix (see below).
While many molecular mechanisms including Rho
signaling underlying tumor invasion have been thought
out based on the results of in vitro motility studies in the
two dimensional culture, tumor cells actually invade into
the three dimensional (3D) space where extensive fibrillar
network of extracellular matrix (ECM) proteins such as
collagen restricts their movement. This in vivo situation led
to the proposal that the invasion of tumor cells requires
coordination of cell adhesion/motility and proteolytic
degradation of ECM substrates, a concept supported by
many in vitro and in vivo model studies [53]. However,
application of inhibitors targeted to ECM-degrading pro-
teases, particularly matrix metalloproteases (MMPs), pro-
vided only weak beneficial effects in tumor models in vivo
in intact animals as well as in clinical trials in humans,
raising a possibility of alternative mode of cell invasion in
the face of MMP inhibition. Friedl and collaborators [54]
examined this issue by studying the behavior of HT1080
fibrosarcoma cells over-expressing MT1-MMP (HT1080/
MT1 cells) invading the 3D-collagen matrix in vitro. They
observed that, without protease inhibition, the HT1080/
MT1 cells adhere the collagen matrix in an integrin-
dependent manner, produce tube-like defects in the matrix
by proteolysis and migrate in the formed tubes. This is
consistent with the classic motility-proteolysis coordination
concept. They, however, found that, when proteolytic
activity was inhibited, this proteolysis-dependent mesen-
chymal movement was converted to the amoeboid move-
ment, in which cells adapt spherical round shape and pass
through the fibrillar network by changing the shape of their
bodies by propulsive squeezing along preformed fiber
strands. They suggested that this mesenchymal-amoeboid
transition is a supramolecular plasticity tumor cells can
adopt in tissue invasion and escape from abrogation of
proteolysis. Sahai and Marshall [55] also examined the
behavior of several tumor cell lines in the 3D matrix and
found that some tumor cell lines migrate through the 3D
matrix in the rounded form, i.e. by contraction of their
bodies. The round form of migration Sahai and Marshall
found apparently corresponds to the amoeboid movement
described by the Friedl group. Sahai and Marshall further
analyzed signal transduction therein and found that the
Rho-ROCK pathway is a major driving force for this mode
of migration, and suggested that inhibition of both
proteases and ROCK may be beneficial for inhibition of
tumor invasion. Sahai and collaborators then extended this
work by showing that cells with rounded morphology
pushed away the collagen in front of them for invasion and
this deformation was dependent on myosin phosphorylation
and ROCK activity [56]. They found that the actomyosin
bundles are formed in a ROCK-dependent manner in the
cell cortex perpendicular to the direction of migration just
behind the invading edge, and suggest that the contraction
of the cell cortex by these actomyosin bundles causes the
cell body to move forward by pushing the collagen matrix
away. A more recent report from this group demonstrated
that localization of ROCK in the above actomyosin bundles
and their contraction is dependent on PDK1 but not on its
kinase activity [57], thus raising an interesting possibility
for interaction of PI-3-kinase pathway and the Rho-ROCK
pathway in tumor invasion.
Thus, the current understanding of tumor invasion is that
there are two modes of tumor cell movement in invasion; one
is the proteolysis-guided mesenchymal movement and the
other is the actomyosin-driven amoeboid movement, and the
inhibition of proteases, particularly matrix metallo-proteases
(MMPs), can convert the mode of migration from the former
to the latter, and inhibition of ROCK may convert the mode
from the latter to the former, or preferentially select the
fraction of tumor cells with the former mode (Fig. 7). While
the latter mode is clearly Rho/ROCK-dependent, there is an
indication that Rho signaling is also implicated in the former
process. MMPs, either membrane bound or secreted, are
localized to specialized structures at the cell-substrate
boundary named podosomes/invadopodia [58]. Podosomes/
invadopodia are dot-shaped actin-enriched contacts encircled
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by columns of integrin-adhesion protein complex that form
plasma membrane extensions to ECM, and in which
activated MMPs accumulate and actively degrade ECM
fibers. While the actin filament assembly for podosome
formation is catalyzed by the Cdc42-Arp2/3-N-WASP
system [58], there are several lines of evidence that Rho
signaling is also somehow involved. For example, inhibition
of Rho induced podosome disruption in human and mouse
dendritic cells and in mouse osteoclast-like cells [59–61],
and constitutively active Rho mutant, V14-RhoA stimulated
podosome assembly in osteoclasts [62]. Since Rho is not
directly involved in podosome assembly, Rho signaling may
be involved in induction of podosome. Podosomes are
induced by activation of Src kinases, either oncogenic
v-Src and a protooncogene, c-Src. Martin and collaborators
[63] examined the podosome formation in Src-transformed
cells, and found that inactivation of Rho by either over-
expression of dominant negative N19-RhoA or botulinum
C3 exoenzyme disrupted the podosome structure in these
cells and strongly inhibits Src-induced proteolytic degrada-
tion of ECM proteins. They also showed that active GTP-
bound form of Rho also accumulate in the podosome.
Interestingly, this inhibitory activity of Rho inactivation on
podosome is not mimicked by inhibition of ROCK with
Y-27632, indicating that the Rho signaling other than ROCK
is important in this process, and functions in situ at the
podosome to maintain these structures.
4 Rho signaling and malignant transformation
Malignant transformation of cells induces, in vitro in cell
culture, morphological changes, reduced serum-dependence
of proliferation, loss of contact inhibition shown by foci
formation and anchorage-independent growth examined by
colony formation in soft agar, and tumor formation when
implanted in vivo. While the prototype of Rho GEFs, Dbl,
was isolated as an oncogene, and over-expression of many
Dbl family protein mutants can induce malignant transfor-
mation [64], over-expression of Rho GTPases such as
RhoA, Rac1 and Cdc42 either in wild type forms or in
activated mutants exhibit little or only weak transforming
activity (see for example, 65). Consistently, no active
mutant of Rho GTPases analogous to that for Ras was
isolated as an oncogene in clinical cancers. On the other
hand, however, it was shown that each of Rho GTPases is
required for Ras-induced transformation [65–69]. For
example, Qiu et al. [67] expressed constitutively active
V14-RhoA or dominant negative N19-RhoA mutant either
alone or together with active Ras mutant, V12-Ras, or
active Raf mutant, RafCAAX, and found co-expression of
N19-RhoA dose-dependently suppressed focus formation
as well as colony formation in soft agar induced either V12
H-Ras or RafCAAX, and reversed the morphology of Ras-
V12 transformed cells, whereas expression of V14-RhoA,
though alone cannot induce transformation, synergizes with
RafCAAX to facilitate transformation. Similar findings
were also reported by Der and collaborators [65, 68]. These
results indicate that Ras mobilizes not only Raf-mediated
kinase cascade but also other signaling pathway(s) for
efficient transformation, and that Rho functions in the latter
pathway(s) to facilitate its process or Rho may exert
permissive effects on these pathways. Interestingly, al-
though Rho is required for Ras-mediated transformation,
the Ras transformants typically lack stress fibers, a hallmark
of Rho action. This paradox indicates that this Rho-
facilitated signaling pathway contains a mechanism to
cause stress fiber dissolution. More recently, Ras utilizes
all three of its downstream signaling pathways, the Raf-
MEK-ERK cascade, the PI-3-kinase signaling and RalGDS
pathway, to induce full transformation [70]. It is possible
that Rho signaling concerts with either or both of the latter
two signaling pathways in Ras-induced transformation
(Fig. 8a).
Following these initial observations, Sahai and Treisman
[71] then examined downstream signaling of Rho involved
in transformation. They first used several point mutants in
the effector loop of Val14RhoA and examined their
synergism with active ΔNRaf in focus formation. Compar-
ing the results obtained in this experiment with specificity
of each mutant in binding to Rho effectors including
ROCK, PKN, mDia2, citron and Rhophilin and activity of
each mutant in other Rho actions such as stress fiber
formation and serum response factor activation, they
concluded that ROCK is involved in this process. They
then used the ROCK inhibitor, Y-27632, and found that Y-
Fig. 7 Two modes of cell migration in the three-dimensional matrix.
Tumor cells exhibit two modes of migration in three-dimensional
matrix, the actomyosin-driven amoeboid movement and the proteol-
ysis-guided mesenchymal movement. The Rho-ROCK pathway is
involved in the former, whereas Cdc42 and possibly Rho with other
effector are involved in the latter mode.
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27632 indeed inhibits transformation induced by activated
Ras, H-Ras-R12, and co-expresison of ΔNRaf and
V14RhoA [72]. On the other hand, although co-expression
of active ROCK mutant with ΔNRaf induced significant
enhancement of transformation induced by ΔNRaf alone,
the extent of enhancement was much lower than that
achieved by co-expression of V14-RhoA and ΔNRaf.
These results indicate that ROCK is required for Rho-
mediated enhancement of Ras-induced transformation but
that it is not the sole Rho effector in this process. The
Treisman’s group further examined possible involvement of
ezrin, a ROCK substrate, in this process, and found that
expression of T567A ezrin mutant insensitive to ROCK
phosphorylaitn interfered with transformation induced by the
active Ras mutant [73]. Sahai et al. [74] further examined
intracellular localization of ROCK in Ras-transformed cells
and found that the majority of ROCK is sequestered in an
inactive pool by sustained ERK-MAP kinase activity under
active Ras. They suggested that this may be one of the
mechanisms for dissolution of stress fibers seen in Ras
transformants. However, they presented no explanation how
requirement for transformation and down-regulation for
dissolution of stress fibers of ROCK can occur at the same
time.
In addition to Ras, Rho signaling may also be implicated
in transformation by Src. v-Src is the oldest oncogene, and
its proto-oncogene, c-Src, is amplified in a variety of
clinical cancers and its activity often correlates with their
invasive potency [75]. Src kinases, both v-Src and c-Src, are
inactive in a soluble non-myristylated form, indicating that
they must be directed to a specific subcellular structure(s) in
order to induce transformation. Src exhibits a variety of
discrete subcellular distribution including plasma mem-
brane, adhesion plaques, cell-cell contact and perinuclear
membranes. Earlier, Hamaguchi and Hanafusa [76] used
various Src mutants, and found correlation between
cytoskeletal association and transforming activity. Liebl
and Martin [77] prepared chimera molecules in which v-Src
was conjugated with motifs targeting to a specific subcel-
lular site, and found that v-Src and not c-Src targeted to
adhesion plaques could induce transformation phenotype,
though the malignant phenotype by this chimera was not
exactly the same as that induced by wild type v-Src. Given
their own findings that translocation of v-Src to the cell
periphery is important for its transformation activity, Frame
and collaborators examined mechanism of peripheral
translocation using temperature-sensitive mutant of v-Src
[78]. They found that v-Src accumulated in the perinuclear
region at the restrictive temperature, and moves to the
periphery upon the shift to the permissive temperature. In
Swiss3T3 fibroblasts, this translocation of v-Src from the
perinuclear pool to the periphery required serum stimula-
tion. They found that, on serum addition, v-Src associates
with serum-induced (Rho-mediated) actin stress fibers and
accumulates in focal adhesions, and that intact actin
filaments are required, while microtubules are dispensable,
for this translocation. They then examined structural and
catalytic requirement of Src for this translocation and found
that the intact SH3 domain is essential for this translocation,
while the myristylation and kinase activity are dispensable
[79, 80]. They further found that stimulation of Swiss3T3
cells expressing GFP-Src construct with LPA, platelet-
derived growth factor (PDGF) and bradykinin, stimuli
known to activate Rho, Rac and Cdc42, respectively,
translocated Src-GFP to focal adhesions, membrane ruffles
and filopodia, respectively [81]. This translocation was
mimicked by co-expression of dominant active Rho
GTPases, V14-RhoA, V12-Rac1 and V12-Cdc42, and
inhibited by expression of dominant negative mutants of
each GTPases. Intriguingly, localization of Src-GFP to
lamellipodia and filopdia was suppressed by inhibition with
N17-Rac1 and N17-Cdc42, but in both cases Src-GFP then
accumulated in focal adhesions. Moreover, treatment with a
specific ROCK inhibitor, Y-27632, not only suppressed of
Rho-mediated accumulation of Src-GFP in focal adhesions
but also that in lamellipodia and filopodia induced by
PDGF and bradykinin, respectively. These results indicate
that Src is originally recruited to focal adhesions in a Rho
and ROCK-dependent manner, and then moves to focal
complexes in lamellipodis or filopodia upon remodeling of
focal adhesions to focal complexes induced by Rac or
Cdc42. The Frame’s group [82] more recently reported that
Src in the prinuclear region and during the transit to the
periphery associates with endosomes, as originally ob-
served by Kaplan et al. [83]. The Src-containing endosomes
partly overlap with those containing RhoB that resides in
the endosome, and the peripheral translocation of Src is
Fig. 8 (a) Rho signaling in Ras-induced transformation. Rho may
facilitate pathways other than the Raf pathway under Ras or promote
transformation in collaboration with these pathways. A part of Rho
action is mediated by ROCK (see text). (b) Involvement of Rho in
translocation of Src. The Rho-mDia/ROCK pathway mediates Src
translocation to focal adhesions and facilitates adhesion turnover.
Whether this pathway also function in elicitation of transformation
and tumorigenicity awaits clarification
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impaired in MEF cells prepared from Rho-B-/- mice, the
defect rescued by re-expression of RhoB in the knockout
cells. They also reported that, when cellular F-actin
abolished by treatment with cytochalasin D reappear with
the washout of the drug, clouds of F-actin become
associated with the RhoB/Src-containing endosomes, and
suggested that such actin structure may function to propel
the endosomes in the cell. The Frame’s group [84] also
examined translocation of Src related kinase, Yes and Fyn,
and found that their translocation to the periphery also
requires intact actin filaments. Interestingly, Fyn is local-
ized to RhoD and not RhoB-containing endosomes, and
this selective localization to the RhoD endosomes is
dependent on palmitoylation of the N-terminal region of
Fyn. Thus, the Frames group has carried out extensive
study on the translocation mechanism of Src and Src-
related kinases, and has found an important link between
Src, actin and Rho GTPases (Fig. 8b). Curiously, however,
they have discussed their results mainly in relation to Src-
induced disassembly of focal adhesions, and not addressed
how critical the pathway they defined is in Src-induced cell
transformation. They have not examined, either, effector
mechanism for actin filament assembly required for translo-
cation of Src and Src-related kinases. Given the requirement
of Rho in this process, a strong candidate is the mDia family
of proteins. As discussed above, Yamana et al. [40] already
reported that depletion of mDia1 resulted in impaired
accumulation of c-Src in focal adhesions of migrating C6
rat glioma cells. Whether the mDia1-mediated mechanism
also operates for elicitation of Src-induced malignant
transformation should be explored in future studies.
5 Perspectives
As we review in this article, Rho signaling consisting of
Rho, mDia and ROCK is apparently involved in elicitation
of various phenotypes of tumor cells, transformation,
motility, transmigration and invasion in vivo, and circum-
ferential evidence has accumulated for strong relation of
this signaling to oncogenic actions of Ras and Src.
Naturally, such information raises many questions. They
include; how does the Rho-ROCK pathway contribute to
Ras-induiced transformation? Does it facilitate signaling
pathway(s) other than the Raf-Erk pathway under Ras? Is
there any Rho-mediated pathway other than ROCK
functioning in Ras-induced transformation? Is the action
of Rho signaling in transformation independent of its action
in invasion or do they represent different aspects of the
same action? Does Rho signaling function not only in Src-
mediated motility and invasion but also in transformation
induced by this oncogene? Are the actions of Rho signaling
for Ras and Src separate and independent or are they
intimately connected in elicitation of transformed pheno-
type by each oncogene? Finally, how much does Rho
signaling contribute to tumorigenesis in intact animals and
in clinical cancers? We are now in a stage where we can
answer some or all of these questions. Clarifying these
questions is hoped to provide an insight into how tumor
cells integrate various signaling pathways including Ras,
Src and Rho for expression of their malignancy.
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